Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Inception of anaRIC biologics as Anacura and RIC combine R&D and GMP activities

With the purpose of supporting customers throughout their entire biological drug development process, GMP specialist Anacura and the R&D-focused R…


Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis a…


MITHRA RECEIVES GMP APPROVAL FOR MYRING™ PRODUCTION

With production GMP approved, Mithra's Myring contraceptive is well on schedule to storm the markets within less than a year.

POPULAR TAGS

PharmaFluidics announces product range extension for its µPACᵀᴹ chromatography chips to serve new biopharma markets

Written by Guest Author on in the category news with the tags , .


Ghent, Belgium, February 10, 2020 - PharmaFluidics NV, an innovative player in the field of analytical chromatography, announces a product range extension into capillary flow rate liquid chromatography (capillary LC).  PharmaFluidics initiates commercial supplies of its new µPAC™ capLC column, bringing unprecedented sensitivity, reproducibility and robustness to a new range of customers worldwide, including the biopharmaceutical industry. PharmaFluidics’ unique high-resolution µPAC™ micro-Chip technology enables separation and detection of individual compounds in complex biological samples such as biopsies, proteome digests, culture media or biopharmaceutical actives, with unmatched precision.

Micro-Chip Chromatography - From nanoflow rates to capillary flow rates

Building upon their award-winning micro Pillar Array technology (µPACᵀᴹ), the new µPAC™ capLC column can be operated at capillary flow rates of 1-15 µL/min. This complements the company’s highly successful and record-setting µPAC™ nanoLC columns, operated at 0.1 to 1.5 µL/min. These ten-fold higher flow rates enable the µPAC™ technology to be used in a broad range of new markets including bioanalytical testing, or (clinical) proteomics and metabolomics. The new µPAC™ capLC column is compatible with all commercially available capillary LC systems and can be integrated smoothly in any capillary LC workflow or experimental set-up.

New biopharma markets to serve

Biopharmaceuticals currently account for 25% of the total pharmaceutical market and monoclonal antibodies (mAbs) are the fastest growing class of therapeutics. The characterization of both new molecules and biosimilars, requires powerful analytical tools. The mAb downstream purification process also needs to be monitored closely, as host-cell proteins — byproducts of the production process ­— can greatly affect the efficiency or the safety of the end product. The µPAC™ technology has already demonstrated its value in these applications. The new µPAC™ capLC column translates these benefits to the operating conditions these industries are routinely working with, allowing them to perform highly sensitive and robust analyses in high throughput.

Katrien Vanhonacker, PharmaFluidics VP Business Development & Sales, says: “This new column is an important addition to our product portfolio. It shows that PharmaFluidics has the technical capability to grow beyond the nanoflow market. The new µPACᵀᴹ capLC column gives us access to a larger instrument installed base and will open doors to new markets. The column will serve the needs of the analytical audience looking for high sensitivity under very robust and reproducible conditions. Therefore, the bioanalytical labs of the biopharma industry are very interested and highly anticipate our solution. Even before the product launch, we have already received requests for applications like host cell protein testing.”

About PharmaFluidics

PharmaFluidics develops and commercializes its unique μPACᵀᴹ range of micro-chip based chromatography columns for use in biomarker, diagnostics and drug research & development applications in the global biotech and pharma industries. The unprecedented, game-changing separation performance of PharmaFluidics’ μPACᵀᴹ chromatography columns allows to identify substantially more compounds in complex biological samples, such as biopsies, proteome digests, culture media or biopharmaceutical actives.

The key expertise and IP estate of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence and pioneer users to develop an increasing range of applications.

For more information, please visit www.pharmafluidics.com

Read more about: , .

RELATED ARTICLES
Inception of anaRIC biologics as Anacura and RIC combine R&D and GMP activities

With the purpose of supporting customers throughout their entire biological drug development process, GMP specialist Anacura and the R&D-focused R…


Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis a…


MITHRA RECEIVES GMP APPROVAL FOR MYRING™ PRODUCTION

With production GMP approved, Mithra's Myring contraceptive is well on schedule to storm the markets within less than a year.

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent XpandInnovation KU Leuven GSK Biowin Janssen Flanders.bio V-Bio Ventures Turnstone Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.